Welcome to our lab (RauhLab), home of translational and transformative myeloid pathology and research! Our focus is on genetic and immune pathogenesis of myeloid cancers, including myelodysplastic syndromes (MDS). More recently, we are expanding our focus to age-related, pre-leukemic, clonal hematopoiesis (called CH or ARCH or CHIP), and the impacts of monocytes, macrophages and neutrophils carrying CHIP mutations (especially in TET2 and DNMT3A) on related cardio-pulmonary, kidney and infectious diseases.
We strive to provide novel and more objective genomic and proteomic tests, in order to detect CHIP and myeloid cancer earlier. By understanding how mutant clones manipulate and respond to the innate immune environment, we hope to discover novel biomarkers and treatment targets. Applying this knowledge, our goal is to provide more personalized diagnosis and care and, ultimately, prevention of myeloid cancers and co-morbid diseases.